💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

DR Horton Bagged $10 Billion in Q3 Revenue, Stock Price Jumps 11%

Published 07/18/2024, 09:12 AM
DHI
-

DR Horton (NYSE:DHI), America’s Builder, reported robust financial results for the third quarter of fiscal 2024. Net income per diluted share increased by 5% to $4.10, up from $3.90 in the same quarter of the previous year.

The company’s net income experienced a modest 1% rise, reaching $1.35 billion compared to $1.34 billion in the third quarter of fiscal 2023. Consolidated revenues also saw an uptick, climbing 2% to $10.0 billion from $9.7 billion in the same quarter last year.

For the nine months ending June 30, 2024, DR Horton reported a notable 11% increase in net income per diluted share, amounting to $10.43 compared to $9.39 in the same period of fiscal 2023.

The company’s net income for this nine-month period rose by 7% to $3.5 billion, up from $3.2 billion in the corresponding period of the previous year. Consolidated revenues for the first nine months of fiscal 2024 increased by 7%, reaching $26.8 billion compared to $25.0 billion in the same period of fiscal 2023.

During the third quarter, DR Horton closed 24,155 homes, a 5% increase from the 22,985 homes closed in the same quarter of fiscal 2023. The value of homes closed also grew by 6% to $9.2 billion.

Net sales orders for the quarter increased by 1% to 23,001 homes, although the sales order value remained flat at $8.7 billion. The company’s rental operations generated $64.2 million in pre-tax income on revenues of $413.7 million, from the sale of 790 single-family rental homes and 610 multi-family rental units.

DR Horton Surpasses EPS and Revenue Expectations in Q3

DR Horton’s performance in the third quarter of fiscal 2024 exceeded market expectations. Analysts had projected an earnings per share (EPS) of $3.77 and revenue of $9.64 billion.

In contrast, the company reported an EPS of $4.10 and revenue of $10.0 billion, surpassing both EPS and revenue forecasts. This marks a significant achievement for DR Horton, especially given the economic challenges such as elevated inflation and mortgage interest rates.

The company’s homebuilding revenue for the third quarter increased by 6% to $9.2 billion, compared to $8.7 billion in the same quarter of the previous year. This growth was driven by a 5% increase in the number of homes closed, which totaled 24,155 homes.

The homebuilding segment’s pre-tax income also saw a 7% increase, reaching $1.6 billion with a pre-tax profit margin of 17.0%.

However, it’s worth noting that the company’s rental operations experienced a decline in pre-tax income, which fell to $64.2 million from $162.1 million in the same quarter of fiscal 2023.

This was primarily due to a decrease in the number of single-family rental homes sold, which dropped to 790 homes from 1,754 homes in the prior year quarter.

Despite this, the overall performance of DR Horton remained strong, with consolidated pre-tax income increasing by 1% to $1.8 billion and a pre-tax profit margin of 18.1%.

DR Horton Expects full-year Year Consolidated Revenues to Range Between $36.8 Billion and $37.2 Billion

Based on the current market conditions and the company’s performance in the first nine months of fiscal 2024, DR Horton has updated its guidance for the full fiscal year.

The company expects consolidated revenues to range between $36.8 billion and $37.2 billion, and anticipates closing between 90,000 and 90,500 homes through its homebuilding operations.

This guidance reflects the company’s confidence in its ability to continue delivering strong financial results despite the challenging economic environment.

DR Horton also reiterated its guidance for cash flow provided by homebuilding operations, projecting approximately $3.0 billion for fiscal 2024.

The company plans to provide additional guidance for its fourth quarter during its conference call, scheduled for today, July 18, 2024. The call will offer further insights into the company’s strategic initiatives and financial outlook.

DR Horton has also announced a new share repurchase authorization totaling $4.0 billion, replacing the previous authorization.

***

Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our website policy prior to making financial decisions.

This article was originally published on The Tokenist. Check out The Tokenist’s free newsletter, Five Minute Finance, for weekly analysis of the biggest trends in finance and technology.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.